Treatment Choice for Advanced Non-small Cell Lung Cancer Patients Who Had Gradual Progression After EGFR-TKIs:32 Cases Report
10.3779/j.issn.1009-3419.2013.10.05
- VernacularTitle:EGFR-TKIs治疗晚期非小细胞肺癌获益后出现缓慢进展的治疗选择：附32例病例总结
- Author:
LIN LIN
1
;
WANG BIN
;
HAO XUEZHI
;
XING PUYUAN
;
LI JUNLING
;
ZHANG XIANGRU
;
SHI YUANKAI
Author Information
1. 100021北京，中国医学科学院北京协和医学院肿瘤医院内科，抗肿瘤分子靶向药物临床研究北京市重点实验室
- Keywords:
Lung neoplasms;
EGFR-TKIs;
Gradual progression;
Overall survival
- From:
Chinese Journal of Lung Cancer
2013;(10):524-528
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective hTe epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used in the treatment of the advanced non-small cell lung cancer (NSCLC), especially in the adeno-carcinoma patients with activating EGFR mutations. But there is no published overview of the following treatment. hTis report through observing the efficacy, toxicity and overall survival of different treatments to the advanced NSCLC patients who had gradual progression atfer EGFR-TKIs, evaluates the inlfuence of the continued treatment and switching chemotherapy. Methods Retrospective review is conducted on 32 cases of advanced NSCLC patients who experienced treatment failure of EGFR-TKIs. One group accepted the continued treatment and the other group accepted the switching chemotherapy. Results hTe median overall survival of the continued treatment group is 36.0 months. hTe respose rate of the switching chemotherapy group is 43.75%, and clinical benefit rate (complete and partial response and stable disease) is 87.5%. The median overall survival is 15.5 months. hTe main toxicities are nausea, vomiting and hematological toxicities. Conclusion For the advanced NSCLC patients who had gradual progression atfer EGFR-TKIs, the continued treatment is one of the acceptable choices.
